Item | Property | Value | Comments |
---|
include | http://hl7.org/fhir/sid/cvx | | |
 Concept | | 01 | | Version: diphtheria, tetanus toxoids and pertussis vaccine | |
 Concept | | 02 | | Version: trivalent poliovirus vaccine, live, oral | |
 Concept | | 03 | | Version: measles, mumps and rubella virus vaccine | |
 Concept | | 04 | | Version: measles and rubella virus vaccine | |
 Concept | | 05 | | Version: measles virus vaccine | |
 Concept | | 06 | | Version: rubella virus vaccine | |
 Concept | | 07 | | Version: mumps virus vaccine | |
 Concept | | 08 | | Version: hepatitis B vaccine, pediatric or pediatric/adolescent dosage | |
 Concept | | 09 | | Version: tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) | |
 Concept | | 10 | | Version: poliovirus vaccine, inactivated | |
 Concept | | 100 | | Version: pneumococcal conjugate vaccine, 7 valent | |
 Concept | | 101 | | Version: typhoid Vi capsular polysaccharide vaccine | |
 Concept | | 102 | | Version: DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine | |
 Concept | | 103 | | Version: meningococcal C conjugate vaccine | |
 Concept | | 104 | | Version: hepatitis A and hepatitis B vaccine | |
 Concept | | 105 | | Version: vaccinia (smallpox) vaccine, diluted | |
 Concept | | 106 | | Version: diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens | |
 Concept | | 107 | | Version: diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation | |
 Concept | | 108 | | Version: meningococcal ACWY vaccine, unspecified formulation | |
 Concept | | 109 | | Version: pneumococcal vaccine, unspecified formulation | |
 Concept | | 11 | | Version: pertussis vaccine | |
 Concept | | 110 | | Version: DTaP-hepatitis B and poliovirus vaccine | |
 Concept | | 111 | | Version: Influenza, live, trivalent, intranasal | |
 Concept | | 112 | | Version: tetanus toxoid, unspecified formulation | |
 Concept | | 113 | | Version: tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) | |
 Concept | | 114 | | Version: meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P) | |
 Concept | | 115 | | Version: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed | |
 Concept | | 116 | | Version: rotavirus, live, pentavalent vaccine | |
 Concept | | 118 | | Version: human papilloma virus vaccine, bivalent | |
 Concept | | 119 | | Version: rotavirus, live, monovalent vaccine | |
 Concept | | 120 | | Version: diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) | |
 Concept | | 121 | | Version: zoster vaccine, live | |
 Concept | | 122 | | Version: rotavirus vaccine, unspecified formulation | |
 Concept | | 123 | | Version: influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile) | |
 Concept | | 125 | | Version: Novel Influenza-H1N1-09, live virus for nasal administration | |
 Concept | | 126 | | Version: Novel influenza-H1N1-09, preservative-free, injectable | |
 Concept | | 127 | | Version: Novel influenza-H1N1-09, injectable | |
 Concept | | 128 | | Version: Novel influenza-H1N1-09, all formulations | |
 Concept | | 129 | | Version: Japanese Encephalitis vaccine, unspecified formulation | |
 Concept | | 130 | | Version: Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated | |
 Concept | | 131 | | Version: Historical record of a typhus vaccination | |
 Concept | | 132 | | Version: Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine. | |
 Concept | | 133 | | Version: pneumococcal conjugate vaccine, 13 valent | |
 Concept | | 134 | | Version: Japanese Encephalitis vaccine for intramuscular administration | |
 Concept | | 135 | | Version: Influenza, high-dose, split virus, trivalent, injectable, preservative free | |
 Concept | | 136 | | Version: meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O) | |
 Concept | | 137 | | Version: HPV, unspecified formulation | |
 Concept | | 138 | | Version: tetanus and diphtheria toxoids, not adsorbed, for adult use | |
 Concept | | 139 | | Version: Td(adult) unspecified formulation | |
 Concept | | 140 | | Version: Influenza, split virus, trivalent, injectable, preservative free | |
 Concept | | 141 | | Version: Influenza, split virus, trivalent, injectable, contains preservative | |
 Concept | | 142 | | Version: tetanus toxoid, not adsorbed | |
 Concept | | 143 | | Version: Adenovirus, type 4 and type 7, live, oral | |
 Concept | | 144 | | Version: seasonal influenza, intradermal, preservative free | |
 Concept | | 146 | | Version: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine. | |
 Concept | | 147 | | Version: Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135) | |
 Concept | | 148 | | Version: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine | |
 Concept | | 149 | | Version: Influenza, live, quadrivalent, intranasal | |
 Concept | | 15 | | Version: influenza virus vaccine, split virus (incl. purified surface antigen)-retired CODE | |
 Concept | | 150 | | Version: Influenza, split virus, quadrivalent, injectable, preservative free | |
 Concept | | 151 | | Version: influenza nasal, unspecified formulation | |
 Concept | | 152 | | Version: Pneumococcal Conjugate, unspecified formulation | |
 Concept | | 153 | | Version: Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free | |
 Concept | | 155 | | Version: Influenza, recombinant, trivalent, injectable, preservative free | |
 Concept | | 158 | | Version: Influenza, split virus, quadrivalent, injectable, contains preservative | |
 Concept | | 16 | | Version: influenza virus vaccine, whole virus | |
 Concept | | 160 | | Version: Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013 | |
 Concept | | 161 | | Version: Influenza, injectable,quadrivalent, preservative free, pediatric | |
 Concept | | 162 | | Version: meningococcal B vaccine, fully recombinant | |
 Concept | | 163 | | Version: meningococcal B vaccine, recombinant, OMV, adjuvanted | |
 Concept | | 164 | | Version: meningococcal B, unspecified formulation | |
 Concept | | 165 | | Version: Human Papillomavirus 9-valent vaccine | |
 Concept | | 166 | | Version: influenza, intradermal, quadrivalent, preservative free, injectable | |
 Concept | | 167 | | Version: meningococcal vaccine of unknown formulation and unknown serogroups | |
 Concept | | 168 | | Version: Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free | |
 Concept | | 169 | | Version: Hep A, live attenuated-IM | |
 Concept | | 17 | | Version: Haemophilus influenzae type b vaccine, conjugate unspecified formulation | |
 Concept | | 170 | | Version: non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) | |
 Concept | | 171 | | Version: Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free | |
 Concept | | 172 | | Version: cholera, WC-rBS | |
 Concept | | 173 | | Version: cholera, BivWC | |
 Concept | | 174 | | Version: cholera, live attenuated | |
 Concept | | 175 | | Version: Human Rabies vaccine from human diploid cell culture | |
 Concept | | 176 | | Version: Human rabies vaccine from Chicken fibroblast culture | |
 Concept | | 177 | | Version: pneumococcal conjugate vaccine, 10 valent | |
 Concept | | 178 | | Version: Non-US bivalent oral polio vaccine (types 1 and 3) | |
 Concept | | 179 | | Version: Non-US monovalent oral polio vaccine, unspecified formulation | |
 Concept | | 18 | | Version: rabies vaccine, for intramuscular injection RETIRED CODE | |
 Concept | | 182 | | Version: Oral Polio Vaccine, Unspecified formulation | |
 Concept | | 183 | | Version: Yellow fever vaccine live - alternative formulation for vaccine shortage | |
 Concept | | 184 | | Version: Yellow fever vaccine, unspecified formulation | |
 Concept | | 185 | | Version: Influenza, recombinant, quadrivalent, injectable, preservative free | |
 Concept | | 186 | | Version: Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservative | |
 Concept | | 187 | | Version: zoster vaccine recombinant | |
 Concept | | 188 | | Version: zoster vaccine, unspecified formulation | |
 Concept | | 189 | | Version: Hepatitis B vaccine (recombinant), CpG adjuvanted | |
 Concept | | 19 | | Version: Bacillus Calmette-Guerin vaccine | |
 Concept | | 190 | | Version: Typhoid conjugate vaccine (non-US) | |
 Concept | | 191 | | Version: meningococcal A polysaccharide vaccine (non-US) | |
 Concept | | 192 | | Version: meningococcal AC polysaccharide vaccine (non-US) | |
 Concept | | 193 | | Version: hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US) | |
 Concept | | 194 | | Version: influenza, Southern Hemisphere, unspecified formulation | |
 Concept | | 195 | | Version: Diphtheria, Tetanus, Poliomyelitis adsorbed | |
 Concept | | 196 | | Version: tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified | |
 Concept | | 197 | | Version: Influenza, high-dose, split virus, quadrivalent, injectable, preservative free | |
 Concept | | 198 | | Version: Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent) | |
 Concept | | 20 | | Version: diphtheria, tetanus toxoids and acellular pertussis vaccine | |
 Concept | | 200 | | Version: influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free | |
 Concept | | 201 | | Version: influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, no preservative | |
 Concept | | 202 | | Version: influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative | |
 Concept | | 203 | | Version: meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free | |
 Concept | | 204 | | Version: Ebola Zaire vaccine, live, recombinant, 1mL dose | |
 Concept | | 205 | | Version: Influenza, adjuvanted, inactivated, quadrivalent, injectable, preservative free | |
 Concept | | 206 | | Version: Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection | |
 Concept | | 207 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | |
 Concept | | 208 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | |
 Concept | | 21 | | Version: varicella virus vaccine | |
 Concept | | 210 | | Version: SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL | |
 Concept | | 211 | | Version: SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose | |
 Concept | | 212 | | Version: SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL | |
 Concept | | 213 | | Version: SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | |
 Concept | | 214 | | Version: Ebola, unspecified | |
 Concept | | 215 | | Version: Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free | |
 Concept | | 216 | | Version: Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free | |
 Concept | | 217 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation | |
 Concept | | 218 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation | |
 Concept | | 219 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation | |
 Concept | | 22 | | Version: DTP-Haemophilus influenzae type b conjugate vaccine | |
 Concept | | 220 | | Version: Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted | |
 Concept | | 221 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | |
 Concept | | 222 | | Version: Tick-borne encephalitis vaccine, unspecified | |
 Concept | | 223 | | Version: Tick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dose | |
 Concept | | 224 | | Version: Tick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL dose | |
 Concept | | 227 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose | |
 Concept | | 228 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose | |
 Concept | | 229 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose | |
 Concept | | 23 | | Version: plague vaccine | |
 Concept | | 230 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose | |
 Concept | | 231 | | Version: influenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative free | |
 Concept | | 24 | | Version: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis | |
 Concept | | 25 | | Version: typhoid vaccine, live, oral | |
 Concept | | 26 | | Version: cholera vaccine, unspecified formulation | |
 Concept | | 28 | | Version: diphtheria and tetanus toxoids, adsorbed for pediatric use | |
 Concept | | 300 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation | |
 Concept | | 301 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation | |
 Concept | | 302 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation | |
 Concept | | 303 | | Version: Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free | |
 Concept | | 304 | | Version: Respiratory syncytial virus (RSV), unspecified | |
 Concept | | 305 | | Version: Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | |
 Concept | | 306 | | Version: Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months | |
 Concept | | 307 | | Version: Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months | |
 Concept | | 308 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose | |
 Concept | | 309 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | |
 Concept | | 31 | | Version: hepatitis A vaccine, pediatric dosage, unspecified formulation | |
 Concept | | 310 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose | |
 Concept | | 311 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | |
 Concept | | 312 | | Version: SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | |
 Concept | | 313 | | Version: SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose | |
 Concept | | 314 | | Version: Respiratory syncytial virus (RSV) vaccine, unspecified | |
 Concept | | 315 | | Version: Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified | |
 Concept | | 316 | | Version: Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free | |
 Concept | | 317 | | Version: Chikungunya, live attenuated vaccine, 0.5 mL, preservative free | |
 Concept | | 318 | | Version: Anthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxis | |
 Concept | | 319 | | Version: Anthrax vaccine, unspecified | |
 Concept | | 32 | | Version: meningococcal polysaccharide vaccine (MPSV4) | |
 Concept | | 320 | | Version: Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative | |
 Concept | | 321 | | Version: Influenza-avian, H5N8, viral-vector, monovalent, injectable, preservative free | |
 Concept | | 322 | | Version: Influenza-avian, H5N8, viral-vector, monovalent, injectable, contains preservative | |
 Concept | | 323 | | Version: Influenza-avian, H5, unspecified formulation | |
 Concept | | 324 | | Version: Poliovirus, inactivated, fractional-dose (fIPV) | |
 Concept | | 326 | | Version: Respiratory syncytial virus (RSV), mRNA, injectable, preservative free | |
 Concept | | 327 | | Version: Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free | |
 Concept | | 33 | | Version: pneumococcal polysaccharide vaccine, 23 valent | |
 Concept | | 35 | | Version: tetanus toxoid, adsorbed | |
 Concept | | 37 | | Version: yellow fever vaccine live | |
 Concept | | 38 | | Version: rubella and mumps virus vaccine | |
 Concept | | 39 | | Version: Japanese Encephalitis Vaccine SC | |
 Concept | | 40 | | Version: rabies vaccine, for intradermal injection | |
 Concept | | 41 | | Version: typhoid vaccine, parenteral, other than acetone-killed, dried | |
 Concept | | 42 | | Version: hepatitis B vaccine, adolescent/high risk infant dosage | |
 Concept | | 43 | | Version: hepatitis B vaccine, adult dosage | |
 Concept | | 44 | | Version: Hepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patient | |
 Concept | | 45 | | Version: hepatitis B vaccine, unspecified formulation | |
 Concept | | 46 | | Version: Haemophilus influenzae type b vaccine, PRP-D conjugate | |
 Concept | | 47 | | Version: Haemophilus influenzae type b vaccine, HbOC conjugate | |
 Concept | | 48 | | Version: Haemophilus influenzae type b vaccine, PRP-T conjugate | |
 Concept | | 49 | | Version: Haemophilus influenzae type b vaccine, PRP-OMP conjugate | |
 Concept | | 50 | | Version: DTaP-Haemophilus influenzae type b conjugate vaccine | |
 Concept | | 500 | | Version: SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown | |
 Concept | | 501 | | Version: SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) | |
 Concept | | 502 | | Version: SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) | |
 Concept | | 503 | | Version: SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) | |
 Concept | | 504 | | Version: SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) | |
 Concept | | 505 | | Version: SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) | |
 Concept | | 506 | | Version: SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology | |
 Concept | | 507 | | Version: SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) | |
 Concept | | 508 | | Version: SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) | |
 Concept | | 509 | | Version: SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) | |
 Concept | | 51 | | Version: Haemophilus influenzae type b conjugate and Hepatitis B vaccine | |
 Concept | | 510 | | Version: SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) | |
 Concept | | 511 | | Version: SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) | |
 Concept | | 512 | | Version: SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz) | |
 Concept | | 513 | | Version: SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax) | |
 Concept | | 514 | | Version: SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D) | |
 Concept | | 515 | | Version: SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901) | |
 Concept | | 516 | | Version: SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | |
 Concept | | 517 | | Version: SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax) | |
 Concept | | 518 | | Version: SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | |
 Concept | | 519 | | Version: SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | |
 Concept | | 52 | | Version: hepatitis A vaccine, adult dosage | |
 Concept | | 520 | | Version: SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech | |
 Concept | | 521 | | Version: SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK | |
 Concept | | 53 | | Version: typhoid vaccine, parenteral, acetone-killed, dried (U.S. military) | |
 Concept | | 54 | | Version: adenovirus vaccine, type 4, live, oral | |
 Concept | | 55 | | Version: adenovirus vaccine, type 7, live, oral | |
 Concept | | 56 | | Version: dengue fever vaccine, tetravalent | |
 Concept | | 62 | | Version: human papilloma virus vaccine, quadrivalent | |
 Concept | | 66 | | Version: Lyme disease vaccine | |
 Concept | | 69 | | Version: parainfluenza-3 virus vaccine | |
 Concept | | 74 | | Version: rotavirus, live, tetravalent vaccine | |
 Concept | | 75 | | Version: vaccinia (smallpox) vaccine | |
 Concept | | 77 | | Version: Tick-borne encephalitis vaccine (non-US) | |
 Concept | | 78 | | Version: tularemia vaccine | |
 Concept | | 80 | | Version: Venezuelan equine encephalitis, live, attenuated | |
 Concept | | 81 | | Version: Venezuelan equine encephalitis, inactivated | |
 Concept | | 82 | | Version: adenovirus vaccine, unspecified formulation | |
 Concept | | 83 | | Version: hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule | |
 Concept | | 84 | | Version: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule | |
 Concept | | 85 | | Version: hepatitis A vaccine, unspecified formulation | |
 Concept | | 88 | | Version: influenza virus vaccine, unspecified formulation | |
 Concept | | 89 | | Version: poliovirus vaccine, unspecified formulation | |
 Concept | | 90 | | Version: rabies vaccine, unspecified formulation | |
 Concept | | 91 | | Version: typhoid vaccine, unspecified formulation | |
 Concept | | 92 | | Version: Venezuelan equine encephalitis vaccine, unspecified formulation | |
 Concept | | 94 | | Version: measles, mumps, rubella, and varicella virus vaccine | |
include | urn:oid:1.2.36.1.2001.1005.17 | | | | |